학술논문

Larotrectinib Treatment for Patients With TRK Fusion-Positive Salivary Gland Cancers.
Document Type
Article
Source
Oncologist; Jun2024, Vol. 29 Issue 6, pe779-e788, 10p
Subject
THERAPEUTIC use of antineoplastic agents
PROTEIN kinase inhibitors
HETEROCYCLIC compounds
ADENOCARCINOMA
PATIENT safety
RESEARCH funding
SALIVARY gland tumors
DESCRIPTIVE statistics
DRUG efficacy
TUMORS
CONFIDENCE intervals
PROGRESSION-free survival
DISEASE progression
TIME
Language
ISSN
10837159
Abstract
Copyright of Oncologist is the property of Oxford University Press / USA and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)